We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > BRII-196

News List

Brii Bio Receives the BioCentury-BayHelix R&D Achievement of the Year Award at the 2021 BioCentury China Healthcare Summit prnasia
November 18, 2021
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens...
NIH trial closes enrolment for Brii Biosciences’ Covid-19 antibodies pharmaceutical-technology
August 06, 2021
Brii Biosciences has reported that the National Institutes of Health (NIH)’s ACTIV-2 clinical trial in the US completed enrolment for the Phase III part assessing its combination treatment, BRII-196 plus BRII-198, for Covid-19.
US closes enrolment in two COVID-19 antibody studies due to futility europeanpharmaceuticalreview
March 08, 2021
The sub-studies evaluating VIR-7831 and BRII-196 with BRII-198 have stopped enrolment based on recommendations from the Data and Safety Monitoring Board.
Trial to evaluate monoclonal antibody therapy for mild-to-moderate COVID-19 europeanpharmaceuticalreview
January 07, 2021
The study will determine if the combination of BRII-196 and BRII-198, two investigational antibodies for SARS-CoV-2, can prevent disease progression.